{"id":"W4236738503","doi":"10.1016/j.annonc.2020.10.103","title":"83MO AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bayer Yakuhin; Eli Lilly Japan; Chugai Pharmaceutical; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Genentech; Aptitude Health; Eli Lilly and Company; Ono Pharmaceutical; Eisai; Daiichi-Sankyo; Array BioPharma; Ipsen; Peter MacCallum Cancer Centre; Sanofi K.K.; Clovis Oncology; University of Ulsan; Pfizer; Incyte; Taiho Pharmaceutical; MSD K.K.; F. Hoffmann-La Roche; Daiichi Sankyo Europe; Servier; Gilead Sciences; Sanofi; Amgen; University of Michigan; Myriad Genetics; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; KRAS; Clinical endpoint; Adverse effect; Internal medicine; Gastroenterology; Colorectal cancer; Cancer; Anemia; Phases of clinical research; Oncology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008253311,0.00103333,0.001055383,0.0002545551,0.0002076622,0.0008131419,0.0004389481,0.001029095,0.005224218],"category_scores_gemma":[0.0007397298,0.0002842314,0.001247118,0.0003652112,0.0005488976,0.000618546,0.0002934867,0.002963034,0.001135227],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007418176,"about_ca_system_score_gemma":0.0008303452,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001250379,"about_ca_topic_score_gemma":0.006420259,"domain_scores_codex":[0.9998068,0.0000758413,0.000007828149,0.00003768191,0.00002418817,0.00004766307],"domain_scores_gemma":[0.9996483,0.00007852691,0.00007000606,0.00001881322,0.00002143451,0.0001629151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6193757,0.01155405,0.009579775,0.002953364,0.002900973,0.0002573982,0.0001824181,0.003273383,0.03719693,0.0009500443,0.02634847,0.2854275],"study_design_scores_gemma":[0.7786775,0.1629326,0.03475479,0.0003298839,0.001957292,0.0005680969,0.0001157152,0.001960723,0.002734926,0.0007577776,0.01513876,0.00007200133],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9675933,0.01327507,0.0006443959,0.003077922,0.0005189533,0.00116269,0.004007616,0.0002808338,0.009439227],"genre_scores_gemma":[0.9605067,0.01246656,0.001797666,0.004583619,0.0003432965,0.0009831854,0.00948591,0.00006956522,0.009763606],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005224218,"threshold_uncertainty_score":0.0174768,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1057723125462467,"score_gpt":0.37538011515654,"score_spread":0.2696078026102933,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}